Document is current
Any future updates will be listed below
-
Authors
Rimmele, Florian
Müller, Britta
Becker-Hingst, Nadine
Wegener, Sophia
Rimmele, Stefanie
Kropp, Peter
Jürgens, Tim P.
-
Funding
Funding for this research was provided by:
Universitätsmedizin Rostock
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 2 March 2023
First Online: 20 March 2023
Competing interests
: FR served on advisory boards and/or as speaker for Allergan, Novartis, Teva, Ipsen. He has received royalties from Elsevier. BM, NB, SW declared no competing interest. SR declared no competing interests. PK served on advisory boards and/or as speaker for Allergan, Novartis, Teva and Lilly. TPJ served on advisory boards and/or as speaker for Allergan, Autonomic Technologies, Desitin, Grünenthal, Hormosan, Novartis, Lilly, Lundbeck, Sanofi and Teva.
